Get the Daily Brief
Latest Biotech News
Transcenta licenses HiCB continuous‑biomanufacturing tech to EirGenix
Transcenta Therapeutics announced a non‑exclusive license of its highly intensified continuous bioprocessing (HiCB) platform to Taiwan CDMO EirGenix, including continuous perfusion and hybrid...
Holiday deal rush: AbbVie buys ex‑China DLL3 T‑cell engager; Gilead picks up Polθ asset
Two licensing deals announced over the holidays reshuffled oncology pipelines. AbbVie paid $100 million upfront for ex‑China rights to Zelgen’s trispecific DLL3 T‑cell engager alveltamig, a deal...
Outlook plunges after third FDA CRL for bevacizumab biosimilar filing
Outlook Therapeutics received a third complete response letter for its bevacizumab formulation ONS‑5010 to treat wet age‑related macular degeneration, triggering an almost 62% intraday stock...
Ultragenyx to cut costs after phase‑3 failures in brittle‑bone trials
Ultragenyx reported failure of two phase‑3 trials in brittle bone disease and announced plans for a major cost‑reduction program. The company said the late‑stage readouts did not meet endpoints...
Directed evolution sharpens adenine base editors – extended guides reduce bystanders
Researchers reported two technical advances aimed at improving adenine base editor (ABE) precision. A study published in Nature Biotechnology used directed evolution to alter enzyme properties and...
Single‑strand deaminases rewrite RNA – multi‑base edits in one transcript
Two complementary papers in Nature Biotechnology unveiled single‑strand deaminase platforms that enable programmable, multi‑base editing of RNA transcripts. One report describes a...
Self‑assembling micelles co‑deliver antifungals – combination works in vivo
Nature Biotechnology published paired advances showing self‑assembling peptide and polymer micelles that co‑deliver antifungal drugs and host‑defense mimics to improve efficacy and safety. One...
SMRTnet AI predicts small‑molecule–RNA interactions without 3D structures
A deep‑learning model named SMRTnet was introduced to predict small‑molecule–RNA interactions using RNA secondary structure and multimodal training data, sidestepping the need for tertiary...
GWAS finds rs17834140‑T variant that restrains clonal hematopoiesis and leukemia
A large GWAS meta‑analysis spanning more than 640,000 individuals identified a rare noncoding variant, rs17834140‑T, that lowers risk of clonal hematopoiesis of indeterminate potential (CHIP) and...
Venetoclax plus palbociclib overcomes resistance in AML – OHSU data
Oregon Health & Science University researchers reported that combining the BCL2 inhibitor venetoclax with the CDK4/6 inhibitor palbociclib produced stronger, more durable anti‑leukemia responses...
Holiday licensing rush: big pharma buys clinical‑stage oncology assets
During the year‑end period major pharma deployed upfront payments to secure clinical oncology assets. Deals include AbbVie’s high‑value optioning of a DLL3‑targeting trispecific T‑cell engager and...
Transcenta licenses HiCB platform to EirGenix for continuous biologics manufacturing
Transcenta Therapeutics granted EirGenix a non‑exclusive license to its highly intensified continuous bioprocessing (HiCB) platform, including continuous perfusion and integrated hybrid continuous...
Ultragenyx prepares major cuts after two failed phase‑3 brittle bone trials
Ultragenyx Pharmaceutical announced phase‑3 failures in two brittle‑bone disease trials and signaled a significant cost‑cutting program in response. The company will restructure spending and...
FDA holiday rejections hit developers: Outlook’s third CRL and surprises for Sanofi, Corcept
Regulatory setbacks piled up over the holiday window as Outlook Therapeutics received a third complete response letter (CRL) from FDA for its bevacizumab biosimilar ONS‑5010, triggering a steep...
Adenine base editors refined—directed evolution cuts bystander noise
Researchers reported two complementary advances on Jan. 2, 2026 that aim to improve the safety profile of CRISPR base editors. One team used directed evolution and 3′-extended guide RNAs to reduce...
RNA editors go modular: single-strand deaminases rewrite transcripts
Two teams published new RNA-editing platforms that expand the scope and precision of transcript rewriting. One Nature Biotechnology paper describes a single-strand deaminase-assisted system that...
Host-defense peptide micelles... co-deliver drugs for potent antifungal combo
Researchers presented converging preclinical evidence that self-assembling peptide micelles can improve antifungal therapy. A Nature Biotechnology report describes a host-defense peptide mimic...
SMRTnet predicts small-molecule–RNA interactions without 3D structures
A new deep-learning framework called SMRTnet predicts small-molecule–RNA interactions using RNA secondary structure and multimodal AI models. The method fuses large-language models with...
Viral vectors retooled to edit macrophage RNA in vivo for sepsis
Scientists engineered a bioengineered viral delivery system that performs RNA editing directly in macrophages to modulate sepsis responses, according to a Nature Communications report. The...
Holiday deals replenish pipelines: AbbVie, Gilead make strategic buys; Blossomhill extends Series B
Big biopharma and venture investors moved over the holidays to shore up oncology and kinase pipelines. AbbVie agreed to pay $100 million upfront for an option to license Zejing’s DLL3-targeting...